immunomodulation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Canada is divided into 15 terrestrial and five marine ecozones. These ecozones encompass over 80,000 classified species of Canadian wildlife, with an equal number yet to be formally recognized or discovered. Although Canada has a low percentage of endemic species compared to other countries, due to human activities, invasive species, and environmental issues in the country, there are currently more than 800 species at risk of being lost. About 65 percent of Canada's resident species are considered "Secure". Over half of Canada's landscape is intact and relatively free of human development. The boreal forest of Canada is considered to be the largest intact forest on Earth, with approximately 3,000,000 square kilometres (1,200,000 sq mi) undisturbed by roads, cities or industry. Since the end of the last glacial period, Canada has consisted of eight distinct forest regions. Approximately 12.1 percent of the nation's landmass and freshwater are conservation areas, including 11.4 percent designated as protected areas. Approximately 13.8 percent of its territorial waters are conserved, including 8.9 percent designated as protected areas. Canada's first National Park, Banff National Park was established in 1885. Canada's oldest provincial park, Algonquin Provincial Park was established in 1893. Established in 2015, Lake Superior National Marine Conservation Area is the world's largest freshwater protected area. Canada's largest national wildlife region, established in 2018, is the Scott Islands Marine National Wildlife Area.
In 1997, the FDA proposed a rule to require pediatric drug trials from the sponsors of New Drug Applications. However, this new rule was successfully preempted in federal court as exceeding the FDA's statutory authority. While this debate was unfolding, Congress used the Food and Drug Administration Modernization Act of 1997 to pass incentives that gave pharmaceutical manufacturers a six-month patent term extension on new drugs submitted with pediatric trial data. The Best Pharmaceuticals for Children Act of 2007 reauthorized these provisions and allowed the FDA to request NIH-sponsored testing for pediatric drug testing, although these requests are subject to NIH funding constraints. In the Pediatric Research Equity Act of 2003, Congress codified the FDA's authority to mandate manufacturer-sponsored pediatric drug trials for certain drugs as a "last resort" if incentives and publicly funded mechanisms proved inadequate.
==== BASIC ==== The BASIC assembly strategy was developed in 2015 and sought to address the limitations of previous assembly techniques, incorporating six key concepts from them: standard reusable parts; single-tier format (all parts are in the same format and are assembled using the same process); idempotent cloning; parallel (multipart) DNA assembly; size independence; automatability. DNA parts and linker design The DNA parts are designed and cloned into storage plasmids, with the part flanked by an integrated prefix (iP) and an integrated suffix (iS) sequence. The iP and iS sequences contain inward facing BsaI restriction sites, which contain overhangs complementary to the BASIC linkers. Like in MODAL, the 7 standard linkers used in BASIC were designed with the R2oDNA Designer software, and screened to ensure that they do not contain sequences with homology to chassis genomes, and that they do not contain unwanted sequences like secondary structure sequences, restriction sites or ribosomal binding sites. Each linker sequence is split into two halves, each with a 4 bp overhang complementary to the BsaI restriction site, a 12 bp double stranded sequence and sharing a 21 bp overlap sequence with the other half. The half that is will bind to the upstream DNA part is known as the suffix linker part (e.g. L1S) and the half that binds to the downstream part is known as the prefix linker part (e.g. L1P). These linkers form the basis of assembling the DNA parts together.
== History == Frank Berger was working in a laboratory of a British drug company, looking for a preservative for penicillin, when he noticed that a compound called mephenesin (or myanesin) calmed laboratory rodents without actually sedating them. Berger subsequently referred to this “tranquilizing” effect in a now-historic article, published by the British Journal of Pharmacology in 1946. However, three major drawbacks existed to the use of mephenesin as a tranquilizer: a very short duration of action, greater effect on the spinal cord than on the brain (resulting in a very low therapeutic index), and a weak activity.
Sources: en.wikipedia.org
Action – Far Cry 3 Artistic Achievement – Journey Audio Achievement – Journey Best Game – Dishonored British Game – The Room Debut Game – The Unfinished Swan Family – Lego Batman 2: DC Super Heroes Game Design – Journey Game Innovation – The Unfinished Swan Mobile & Handheld – The Walking Dead Online – Browser – SongPop Online Multiplayer – Journey Original Music – Journey Performer – Danny Wallace (as the narrator, Thomas Was Alone) Sports/Fitness – New Star Soccer Story – The Walking Dead Strategy – XCOM: Enemy Unknown BAFTA Ones to Watch Award (in association with Dare to Be Digital) – Starcrossed Academy Fellowship – Gabe Newell
TKIs target KIT and can deplete the number of mast cells, but inhibit other tyrosine kinases as well causing side effects. The TKI midostaurin, which has multiple targets, was approved for the treatment of advanced systemic mastocytosis (ASM) in 2017. Avapritinib was approved for ASM in 2021. Anti-KIT mAbs also have been evaluated in chronic urticaria and are reported to reduce symptoms. They appear to induce MC deficiency and reduce serum tryptase.
In 1978, Hild joined Strasbourg as coach of the reserve team. The role required him to scout, so Hild wanted an experienced player to work with the youth while he was away. Both Hild and Frantz recommended Wenger, which convinced manager Gilbert Gress to appoint him. Wenger's playing career at the age of 28 began to wane, but he never anticipated a role in the first team. Working for Strasbourg, however, presented him his first full-time job at the club he supported as a young boy. Hild moved Wenger from midfield to central defence, where he was positioned as a sweeper in reserve games. In November 1978, he made his debut for the first team against MSV Duisburg in the UEFA Cup (a match Strasbourg lost 4–0) and a month later, Wenger played against champions Monaco in the First Division. At the end of the 1978–79 season, RC Strasbourg won the league; Wenger did not join in the celebrations as he was preoccupied with the youth team. He made his final appearance for the senior side in 1979. Wenger spent the last two years of his playing career predominantly running Strasbourg's reserve and youth team. He became conscious of the importance of speaking English, and during his holidays enrolled on a three-week language course at the University of Cambridge. Wenger also studied for his coaching badge at the Centre de ressources, d'expertise et de performance sportives (CREPS) in Strasbourg – this consisted of a course to coach children, followed by an intensive six-day course which led up to the national coaching badge.
The process of nixtamalization was first developed in Mesoamerica, where maize was originally cultivated. The earliest evidence is found in Guatemala's southern coast, with equipment dating from 1200 to 1500 BCE. How nixtamalization was discovered is not currently known with certainty, but it may have been through the use of hot cooking stones to boil corn in early cultures which did not have cooking vessels robust enough to put directly on fire or coals. In limestone-bedrock regions like those in Guatemala and southern Mexico, heated chunks of limestone would naturally be used, and experiments show that hot limestone makes the cooking water sufficiently alkaline to cause nixtamalization. Archaeological evidence of this conjecture has been found in southern Utah. The Aztec and Maya civilizations developed nixtamalization by using slaked lime (calcium hydroxide, or "cal") and lye (potassium hydroxide) to create alkaline solutions. The Chibcha people to the north of the ancient Inca also used calcium hydroxide, while the tribes of North America used soda ash. The nixtamalization process was very important in the early Mesoamerican diet, as there is very little niacin in corn and the tryptophan within is unavailable without processing. A population that depends on untreated maize as a staple food risks malnourishment and is more likely to develop deficiency diseases such as pellagra, niacin deficiency, or kwashiorkor, the absence of certain amino acids that maize is deficient in. Maize cooked with lime or other alkali provided bioavailable niacin to Mesoamericans.
=== Selected books === Mechanisms of Drug Resistance in Neoplastic Cells (1988) ISBN 9780127633626 Preclinical and Clinical Modulation of Anticancer Drugs (1993) ISBN 9780849372919 Basic Science of Cancer (2000) ISBN 9781468484397 Advances in Cancer Research (2014) ISBN 9780124071902
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.